{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:43:04Z","timestamp":1792446184516,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T00:00:00Z","timestamp":1549411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32CA009515"],"award-info":[{"award-number":["T32CA009515"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL007093"],"award-info":[{"award-number":["T32HL007093"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The clinical and procedural parameters that affect the optimal collection of lymphocytes for the production of chimeric antigen receptor (CAR) T cells remain undefined but are increasingly important, as commercial products are now available. We evaluated determinants of low lymphocyte collection efficiency (CE) and the rate of successful CAR T\u2010cell manufacture in middle\u2010aged and older adults with advanced B\u2010cell malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY DESIGNS AND METHODS<\/jats:title>\n                    <jats:p>Mononuclear cell collections using two apheresis platforms (COBE Spectra and Spectra Optia, Terumo BCT) from patients participating in a CD19\u2010directed CAR T\u2010cell therapy trial were reviewed. Patient\u2010 and disease\u2010specific factors, peripheral blood counts, apheresis parameters, and product cell counts were analyzed to determine effects on lymphocyte CE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Ninety\u2010two apheresis events from patients with acute lymphocytic leukemia (ALL) (n\u2009=\u200928), chronic lymphocytic leukemia (n\u2009=\u200918), and non\u2010Hodgkin lymphoma (n\u2009=\u200946) were available for analysis. Forty\u2010one collections (45%) had a lymphocyte CE of &lt;40%. On multivariable analysis, age (every 10\u2010year increase, odds ratio [OR]\u2009= 1.51; p\u2009= 0.034), disease type (chronic lymphocytic leukemia vs. ALL, OR = 0.24; p\u2009= 0.052; non\u2010Hodgkin lymphoma vs. ALL, OR = 0.20; p\u2009= 0.009) and precollection platelets (every 10 \u00d7 10\n                      <jats:sup>3<\/jats:sup>\n                      \/\u03bcL increase, OR = 1.07; p\u2009= 0.005) were appreciably associated with a lymphocyte CE of &lt;40%. No major apheresis complications occurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Lymphocyte collection at our center was well tolerated and 100% successful in manufacturing CD19\u2010directed CAR T cells from adult patients with B\u2010cell malignancies despite low CE in some patients. A diagnosis of ALL, advancing age, and higher preapheresis platelet counts were observed to be associated with low CE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/trf.15178","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T22:39:48Z","timestamp":1549492788000},"page":"1773-1780","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B\u2010cell malignancies"],"prefix":"10.1111","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6702-9057","authenticated-orcid":false,"given":"Sherilyn A.","family":"Tuazon","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Washington"},{"name":"University of Washington Department of Medicine, Division of Oncology Seattle Washington"},{"name":"Seattle Cancer Care Alliance Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Washington"},{"name":"Seattle Cancer Care Alliance Seattle Washington"},{"name":"University of Washington Department of Medicine, Division of Hematology Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Gooley","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Eunson","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maloney","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Washington"},{"name":"University of Washington Department of Medicine, Division of Oncology Seattle Washington"},{"name":"Seattle Cancer Care Alliance Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron J.","family":"Turtle","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Washington"},{"name":"University of Washington Department of Medicine, Division of Oncology Seattle Washington"},{"name":"Seattle Cancer Care Alliance Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Linenberger","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Washington"},{"name":"Seattle Cancer Care Alliance Seattle Washington"},{"name":"University of Washington Department of Medicine, Division of Hematology Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Connelly\u2010Smith","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center Clinical Research Division Seattle Washington"},{"name":"Seattle Cancer Care Alliance Seattle Washington"},{"name":"University of Washington Department of Medicine, Division of Hematology Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_8_3_1","unstructured":"FDA approves CAR\u2010T cell therapy to treat adults with certain types of large B\u2010cell lymphoma [monograph on the Internet]. 2017. Available from:https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm581216.htm."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_8_6_1","unstructured":"FDA approval brings first gene therapy to the United States [monograph on the Internet]. 2017. Available from:https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm574058.htm"},{"key":"e_1_2_8_7_1","unstructured":"FDA approves tisagenlecleucel for adults with relapsed or refractory large B\u2010cell lymphoma [monograph on the Internet]. 2018. Available from:https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm606540.htm"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2016.03.001"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14003"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.247"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_8_12_1","first-page":"306","volume-title":"Cellular therapy: principles, methods, and regulations","author":"Connelly\u2010Smith LSLLM","year":"2016"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2017.37.4.327"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21319"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12506"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14094"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani R","year":"1996","journal-title":"J R Stat Soc B Methodol"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-002-0027-y"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14569"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03787.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15178","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/trf.15178","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.15178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T12:07:56Z","timestamp":1720958876000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.15178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1111\/trf.15178"],"URL":"https:\/\/doi.org\/10.1111\/trf.15178","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]},"assertion":[{"value":"2018-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}